A Prescription Support Tool for Oral Antithrombotic Combinations

Overview

From a systematic review of international guidelines (2012-2018), a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy will be developed. Guidelines dealing with the use of oral ATs for non-valvular atrial fibrillation, coronary artery disease, ischemic stroke, valvular heart disease, peripheral artery disease and venous thromboembolism in adults will be included. These pathologies were selected because most prescriptions of ATs are related to neuro-cardiovascular diseases and because this study would provide a synthesis relevant for clinicians in charge of the follow-up of patients with oral AT combinations. Studies are needed to assess the impact of this tool on appropriate prescribing.

Full Title of Study: “Evaluation of a Prescription Support-tool for Chronic Management of Oral Antithrombotic Combinations in Adults: Protocol of a Randomized Controlled Trial Using Clinical Vignettes”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 14, 2019

Detailed Description

Oral antithrombotic (AT) drugs are widely implicated in serious and preventable bleeding events, which justifies the implementation of risk minimization actions. Avoiding inappropriate oral AT combinations is a major concern, particularly for patients with multiple chronic conditions. The first step is to provide fast and easy access to the latest recommendations. From a systematic review of international guidelines (2012-2018), a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy will be developed. Our main objective in this study is to evaluate the accuracy of this tool by measuring the appropriateness of oral AT prescriptions according to the most recent guidelines. Methods and analysis: In this web-based randomized controlled trial, participating French general practitioners and cardiologists in the outpatient setting will be randomized by use or not of the prescription support-tool. They will be asked to provide the number of drugs, drug class, duration and dosage of ATs, within a time window of 10 minutes, for 3 different clinical situations presented as clinical vignettes (multiple-choice questions). The scientific committee has created and validated 30 clinical vignettes illustrating outpatient clinical situations for which the use of oral ATs (single, dual or triple therapy) is recommended or not according to the guidelines. All data will be treated anonymously. Ethics and dissemination: If the prescription support-tool is associated with more appropriate prescription of AT combinations, its dissemination to further evaluate outcome data including haemorrhage, ischemic events, and death will be considered.

Interventions

  • Other: Evaluate the impact of a prescription support tool
    • From a systematic review of international guidelines (2012-2018), we developed a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy. In the experimental group, the tool will be provided with an explanatory guide. Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (thanks to the tool) the “right prescription” of ATs by answering a multiple-choice question, with the number, type, duration and dosage of AT provided.

Arms, Groups and Cohorts

  • Experimental: Experimental arm
  • No Intervention: Control arm
    • Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (without the tool) the “right prescription” of ATs by answering a multiplechoice question, with the number, type, duration and dosage of AT provided.

Clinical Trial Outcome Measures

Primary Measures

  • The primary outcome measure is the rate of the “right prescription of oral ATs” as defined according to the guidelines in terms of number, class, duration and dosage between the two groups.
    • Time Frame: Day one
    • How will be defined the “right prescription of oral ATs” : From a systematic review of international guidelines (2012-2018), has been developed, a prescription support-tool synthesizing 70 national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy. The scientific committee of this study (cardiologist, internist-geriatricians, general practitioner and epidemiologists) created and validated 30 clinical vignettes. The expert committee of this study had to review all clinical vignettes with the prescription support-tool (external validation) to confirm their agreement with clinical practice and their readability. Thus, the “right prescription of oral ATs” was defined a priori (right or false) thanks to the prescription support tool and validated by the expert committee and the scientific committee.

Secondary Measures

  • The rate of the “right prescription of oral ATs” performed by physicians’ specialty.
    • Time Frame: Day one
    • Physicians’ specialty: french physicians who are involved in outpatient settings, including general practitioners and cardiologists. Physicians with an exclusive hospital practice will not be considered.
  • The difference between the control and intervention groups in the degree of confidence physicians have in their AT prescriptions in line with the guidelines.
    • Time Frame: Day one
    • The degree of confidence was defined a priori with this question: “On a scale of 0 to 10, what is your degree of confidence in the adequacy of your prescription in relation to the guidelines?”

Participating in This Clinical Trial

Inclusion Criteria

  • French practicing physicians who are involved in outpatient settings, including general practitioners and cardiologists. Exclusion Criteria:

  • Physicians with an exclusive hospital practice.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assistance Publique – Hôpitaux de Paris
  • Collaborator
    • Sorbonne University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Lorène ZERAH, M.D, Principal Investigator, APHP / INSERM

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.